RU2013122843A - Гликоформы антитела против фолатного рецептора альфа - Google Patents
Гликоформы антитела против фолатного рецептора альфа Download PDFInfo
- Publication number
- RU2013122843A RU2013122843A RU2013122843/10A RU2013122843A RU2013122843A RU 2013122843 A RU2013122843 A RU 2013122843A RU 2013122843/10 A RU2013122843/10 A RU 2013122843/10A RU 2013122843 A RU2013122843 A RU 2013122843A RU 2013122843 A RU2013122843 A RU 2013122843A
- Authority
- RU
- Russia
- Prior art keywords
- amino acid
- acid sequence
- seq
- monoclonal antibody
- internalization
- Prior art date
Links
- 229940014144 folate Drugs 0.000 title 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 title 1
- 235000019152 folic acid Nutrition 0.000 title 1
- 239000011724 folic acid Substances 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 74
- 102000010451 Folate receptor alpha Human genes 0.000 claims abstract 25
- 108050001931 Folate receptor alpha Proteins 0.000 claims abstract 25
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims abstract 14
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract 12
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract 11
- 239000004472 Lysine Substances 0.000 claims abstract 11
- 210000004899 c-terminal region Anatomy 0.000 claims abstract 11
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims abstract 11
- 210000004027 cell Anatomy 0.000 claims 12
- 238000000034 method Methods 0.000 claims 12
- 238000004113 cell culture Methods 0.000 claims 7
- 230000003247 decreasing effect Effects 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 239000001301 oxygen Substances 0.000 claims 5
- 230000007935 neutral effect Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 3
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 3
- 229930182830 galactose Natural products 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims 3
- 101100186981 Arabidopsis thaliana NGA2 gene Proteins 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- -1 low temperature Chemical compound 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 101150026078 MAN5 gene Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 201000001343 fallopian tube carcinoma Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000003101 oviduct Anatomy 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39481210P | 2010-10-20 | 2010-10-20 | |
| US61/394,812 | 2010-10-20 | ||
| PCT/US2011/056966 WO2012054654A2 (en) | 2010-10-20 | 2011-10-19 | Anti-folate receptor alpha antibody glycoforms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013122843A true RU2013122843A (ru) | 2014-11-27 |
Family
ID=45975873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013122843/10A RU2013122843A (ru) | 2010-10-20 | 2011-10-19 | Гликоформы антитела против фолатного рецептора альфа |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20120164137A1 (enExample) |
| EP (1) | EP2629798A4 (enExample) |
| JP (1) | JP2014505012A (enExample) |
| KR (1) | KR20140032944A (enExample) |
| CN (1) | CN103347537A (enExample) |
| AU (2) | AU2011317088B2 (enExample) |
| BR (1) | BR112013009275A2 (enExample) |
| CA (1) | CA2815080A1 (enExample) |
| IL (1) | IL225579A0 (enExample) |
| MX (1) | MX2013004202A (enExample) |
| RU (1) | RU2013122843A (enExample) |
| WO (1) | WO2012054654A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060239910A1 (en) * | 2005-04-22 | 2006-10-26 | Morphotek Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| ES2766836T3 (es) * | 2012-05-15 | 2020-06-15 | Eisai Inc | Métodos para el tratamiento de cáncer gástrico |
| HRP20200482T1 (hr) * | 2012-08-31 | 2020-06-26 | Immunogen, Inc. | Dijagnostičke analize i setovi za detekciju folat receptora 1 |
| CA2893378A1 (en) * | 2012-12-07 | 2014-06-12 | Kyowa Hakko Kirin Co., Ltd. | Anti-folr1 antibody |
| US20140271622A1 (en) * | 2013-03-14 | 2014-09-18 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| US9677105B2 (en) | 2013-03-14 | 2017-06-13 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| US8956830B2 (en) | 2013-03-14 | 2015-02-17 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| TWI771890B (zh) | 2013-03-14 | 2022-07-21 | 美商安美基公司 | 用於增加重組蛋白質之甘露糖含量之方法 |
| CA2921975C (en) | 2013-08-30 | 2024-02-13 | Immunogen, Inc. | Antibodies and assays for detection of folate receptor 1 |
| EP2871190A1 (en) * | 2013-11-11 | 2015-05-13 | ATLAB Pharma | Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity |
| MA40972B1 (fr) | 2014-11-20 | 2020-11-30 | Hoffmann La Roche | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t ciblant folr1 et cd3 |
| JP6944369B2 (ja) | 2014-11-20 | 2021-10-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｔ細胞活性化二重特異性抗原結合分子ｃｄ３ ａｂｄ葉酸受容体１（ｆｏｌｒ１）及びｐｄ−１軸結合アンタゴニストの併用療法 |
| PT3221357T (pt) | 2014-11-20 | 2020-07-28 | Hoffmann La Roche | Cadeias leves comuns e métodos de utilização |
| EP3227454B1 (en) | 2014-12-01 | 2020-01-29 | Amgen Inc. | Process for manipulating the level of glycan content of a glycoprotein |
| IL257531B2 (en) | 2015-09-17 | 2023-04-01 | Immunogen Inc | Medicinal compositions containing anti-folr1 immunoconjugates |
| EA202092125A1 (ru) | 2018-03-13 | 2020-12-15 | Фейнз Терапьютикс, Инк. | Антитела против рецептора фолата 1 и их применения |
| KR102275930B1 (ko) * | 2018-03-14 | 2021-07-12 | (주)알테오젠 | Folr1에 특이적으로 결합하는 항체 및 그의 용도 |
| CN118344485B (zh) * | 2024-06-18 | 2024-10-15 | 南京欧凯生物科技有限公司 | 抗叶酸及其结合蛋白复合物的单克隆抗体或其抗原结合片段、其制备方法及应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1648511A1 (en) * | 2003-07-29 | 2006-04-26 | Morphotek, Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
| JP4805848B2 (ja) * | 2004-02-12 | 2011-11-02 | モルフォテック、インク． | 腫瘍抗原の生物活性を特異的に阻止するモノクローナル抗体 |
| AU2005274905B2 (en) * | 2004-08-04 | 2010-12-23 | Mentrik Biotech, Llc | Variant Fc regions |
| CN101374545B (zh) * | 2005-04-15 | 2012-03-28 | 免疫基因公司 | 消除肿瘤中的异质或混合细胞群体 |
| US20060239910A1 (en) * | 2005-04-22 | 2006-10-26 | Morphotek Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| CN103242451B (zh) * | 2005-12-16 | 2017-11-21 | Ibc医药公司 | 基于免疫球蛋白的多价生物活性装配体 |
| WO2011116387A1 (en) * | 2010-03-19 | 2011-09-22 | Tetragenetics, Inc. | Production of aglycosylated monoclonal antibodies in ciliates |
-
2011
- 2011-10-19 MX MX2013004202A patent/MX2013004202A/es unknown
- 2011-10-19 CA CA2815080A patent/CA2815080A1/en not_active Abandoned
- 2011-10-19 JP JP2013535058A patent/JP2014505012A/ja active Pending
- 2011-10-19 KR KR1020137012669A patent/KR20140032944A/ko not_active Withdrawn
- 2011-10-19 RU RU2013122843/10A patent/RU2013122843A/ru not_active Application Discontinuation
- 2011-10-19 US US13/277,161 patent/US20120164137A1/en not_active Abandoned
- 2011-10-19 CN CN2011800503838A patent/CN103347537A/zh active Pending
- 2011-10-19 EP EP11835098.2A patent/EP2629798A4/en not_active Withdrawn
- 2011-10-19 BR BR112013009275A patent/BR112013009275A2/pt not_active Application Discontinuation
- 2011-10-19 WO PCT/US2011/056966 patent/WO2012054654A2/en not_active Ceased
- 2011-10-19 AU AU2011317088A patent/AU2011317088B2/en not_active Ceased
-
2013
- 2013-04-04 IL IL225579A patent/IL225579A0/en unknown
-
2016
- 2016-04-04 AU AU2016202082A patent/AU2016202082A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014505012A (ja) | 2014-02-27 |
| MX2013004202A (es) | 2013-10-17 |
| EP2629798A4 (en) | 2014-05-28 |
| CN103347537A (zh) | 2013-10-09 |
| AU2011317088A1 (en) | 2013-05-02 |
| AU2011317088B2 (en) | 2016-01-21 |
| WO2012054654A2 (en) | 2012-04-26 |
| CA2815080A1 (en) | 2012-04-26 |
| BR112013009275A2 (pt) | 2017-06-20 |
| IL225579A0 (en) | 2013-06-27 |
| EP2629798A2 (en) | 2013-08-28 |
| US20120164137A1 (en) | 2012-06-28 |
| WO2012054654A3 (en) | 2012-08-02 |
| AU2016202082A1 (en) | 2016-04-28 |
| KR20140032944A (ko) | 2014-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013122843A (ru) | Гликоформы антитела против фолатного рецептора альфа | |
| JP2014505012A5 (enExample) | ||
| AU2025204722A1 (en) | Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof | |
| KR102244173B1 (ko) | 세포상해 유도 치료제 | |
| JP6794348B2 (ja) | ヒト化抗ｏｘ４０抗体及びその使用 | |
| CN102712923A (zh) | 抗IgA1抗体 | |
| RU2534343C1 (ru) | Способ получения моноклональных антител к белку р30 вируса африканской чумы свиней с использованием рекомбинантных конструкций | |
| CN104884617A (zh) | 抗folr1抗体 | |
| IL310938A (en) | Anti-CCR8 antibodies and their uses | |
| WO2020234399A1 (en) | Novel anti-cd25 antibodies | |
| ES2893536T3 (es) | Método para preparar anticuerpo mediante la regulación del contenido de azúcares del anticuerpo | |
| US20240002503A1 (en) | Novel anti-lilrb2 antibodies and derivative products | |
| US20220144938A1 (en) | Identification and targeting of tumor promoting carcinoma associated fibroblasts for diagnosis and treatment of cancer and other diseases | |
| JP2022033851A (ja) | 癌マーカーおよび治療標的としてのグリピカン２ | |
| CA3143989A1 (en) | Targeting alpha3beta1 integrin for treatment of cancer and other diseases | |
| WO2021056025A2 (en) | Anti-epha10 antibodies and methods of use thereof | |
| WO2022106663A1 (en) | Anti-cd25 antibodies | |
| RU2013139743A (ru) | Гуманизированное моноклональное антитело, специфичное к синдекану-1 | |
| CN107460221B (zh) | 一种降低抗pd-l1抗体中蛋白聚合物的细胞培养方法 | |
| CN104651314B (zh) | 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子 | |
| Bai et al. | Advances in immunological sorting of X and Y chromosome-bearing sperm: from proteome to sex-specific proteins | |
| AU2021380966A1 (en) | Anti-cd25 antibodies | |
| RU2535982C1 (ru) | Штамм культивируемых гибридных клеток животного mus musculus l. cchfv vd-1-продуцент моноклонального антитела 4g4/b6 к вирусу крым-конго геморрагической лихорадки | |
| WO2022150803A1 (en) | AN AGR2Xcd3 BISPECIFIC ENGAGER FOR THE TREATMENT OF CANCER | |
| CN121248787A (zh) | 一种人源化抗人muc1单克隆抗体及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160617 |